Income statement
CAD
Annual
| Metric | 2025 | 2024 | 2023 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -11K | 0 | -33K | -62K | -65K |
| Operating Income | -3M | -3M | -3M | -1M | -1M |
| EBITDA | -3M | -3M | -3M | -1M | -1M |
| Net Income | -3M | -3M | -3M | -1M | -1M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.039
+0.00% today
1Y Change
-16.48%
Window
Jun 23, 2025 → May 29, 2026
Coverage: 236 bars · Jun 23, 2025 → May 29, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Telo Genomics Corp. (TDSGF) is a Healthcare stock with a market cap of $10.00M and listed on OTC. The stock last traded around $0.04 and down 16.5% across the available one-year price window (Jun 23, 2025 → May 29, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +40.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +40.0%, free cash flow +5.4% with operating margin 0.0% and ROIC 663.9%. Stock Foundry combines TDSGF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TDSGF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TDSGF Max Drawdown
-63.75%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TDSGF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$1.2M
-16.1% YoY
Free Cash Flow
-$1.1M
+38.8% YoY
Revenue Growth
+0.0%
EPS Growth
+40.0%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
CAD
| Metric | 2025 | 2024 | 2023 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -11K | 0 | -33K | -62K | -65K |
| Operating Income | -3M | -3M | -3M | -1M | -1M |
| EBITDA | -3M | -3M | -3M | -1M | -1M |
| Net Income | -3M | -3M | -3M | -1M | -1M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CAD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 580K | 796K | 3M | 3M | 4M |
| Total Assets | 669K | 966K | 3M | 3M | 4M |
| Total Liabilities | 291K | 376K | 313K | 230K | 154K |
| Shareholder Equity | 515K | 590K | 3M | 3M | 4M |
| Total Debt | 0 | 0 | 33K | 40K | 40K |
| Net Debt | -580K | -796K | -3M | -3M | -4M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
1M
+38.5% YoY
Capital Expenditures
9K
+63.0% YoY
Free Cash Flow
1M
+38.8% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-990.6%
Debt / Equity
-0.29x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.